Medmarc Insurance Group

Medmarc Insurance Group

Medmarc Insurance Group was founded in 1979 by the Health Industry Manufacturers Association — AdvaMed's predecessor — to solve a structural gap: conventional carriers either wouldn't write liability coverage for early-stage medical-device firms or priced it as generic manufacturing risk. Medmarc's sole underwriting focus is life-sciences and medical-technology companies that develop, test, and commercialize regulated healthcare products. The firm's principal, Karen Murphy, runs the day-to-day operation as President of Life Sciences. The firm writes three primary lines: products liability for finished medical devices and diagnostics, clinical-trial liability that protects sponsors and investigators during FDA-regulated studies, and errors-and-omissions for professional services. Medmarc does not behave like a generalist insurer with a side bet on healthcare — its claims, underwriting, and risk-management teams work exclusively with medtech portfolios. The underwriting footprint spans the United States and Canada, with dedicated claims handlers and regional business-development representatives covering all 50 states plus Canadian markets. Medmarc has been a subsidiary of ProAssurance Corporation since ProAssurance acquired it for $153.7 million in 2013. Subsequent corporate moves have redrawn the ownership stack: in May 2026, ProAssurance entered a definitive agreement to be acquired by The Doctors Company, a physician-owned medical-malpractice carrier. The deal puts Medmarc under a parent that is itself deeply specialized in healthcare liability, reinforcing the firm's narrow-service structure rather than diluting it. Medmarc maintains dedicated offices in Chantilly, Virginia; the firm does not disclose total investable assets or professionals count. Structurally, Medmarc differs from most asset-owner peers in this dataset because its capital base is not discretionary wealth — it is statutory policyholder surplus (claims-paying reserves) held inside a regulated insurance entity. The firm does not operate as a family office, a fund manager, or an allocator in the traditional sense. Its "deployment" is premium float; its "portfolio" is the risk book of medtech manufacturers. That architecture makes Medmarc a sector-liquidity provider — it supplies balance-sheet capacity to an industry that conventional markets have historically avoided — rather than an LP or co-investor.